Targeting nuclear receptors in cancer-associated fibroblasts as concurrent therapy to inhibit development of chemoresistant tumors

Most anticancer therapies to date focus on druggable features of tumor epithelia. Despite the increasing repertoire of treatment options, patient responses remain varied. Moreover, tumor resistance and relapse remain persistent clinical challenges. These observations imply an incomplete understandin...

Descripción completa

Detalles Bibliográficos
Autores principales: Chan, J S K, Sng, M K, Teo, Z Q, Chong, H C, Twang, J S, Tan, N S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2018
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5770601/
https://www.ncbi.nlm.nih.gov/pubmed/28892046
http://dx.doi.org/10.1038/onc.2017.319

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5770601/
https://www.ncbi.nlm.nih.gov/pubmed/28892046
http://dx.doi.org/10.1038/onc.2017.319

Ejemplares similares